Request for Information (RFI): To Inform the Development of the 2026-2030 National HIV/AIDS Strategy and the National Strategic Plans for Sexually Transmitted Infections, Vaccines, and Viral Hepatitis, 81087-81088 [2024-22948]

Download as PDF Federal Register / Vol. 89, No. 194 / Monday, October 7, 2024 / Notices lotter on DSK11XQN23PROD with NOTICES1 IV. Questions for Industry (1.) What measures would be required to transition to electric, non-fossil fuel using equipment for major building systems (heating, cooling, ventilation, and domestic hot water), upon the equipment’s replacement or end-of-life? (a.) What are the constraints or obstacles associated with this transition? (b.) Please provide an estimate of the impact, if any, that electrification of building equipment would have on rental rates for government leases. Please identify the estimated costs and savings associated with implementing electrification. (2.) What are the steps needed to shift toward using energy efficient equipment for building systems that follow the minimum performance requirements of Energy Star or FEMP-designated program standards (upon replacement or end-of-life)? (a.) Are there challenges with obtaining energy efficient equipment and components for major building systems, or following the minimum performance requirements of Energy Star or FEMP-designated program standards for a federal leased space? If yes, what are those market challenges? (b.) What impact on rental rates, if any, would installing energy efficient equipment and components for major building systems, or following the minimum performance requirements of Energy Star or FEMP-designated program standards? (3.) If periodic recommissioning is required, what is the appropriate frequency that major building systems should be recommissioned? (a.) Are there commercial industry standards for building recommissioning that we should consider using? (b.) What parameters should we consider using if we chose to include recommissioning requirements (eg: percentage of government occupancy; size of lease; term of lease)? (c.) What impact would periodic recommissioning requirements have on rental rates? (4.) Are building owners currently required to track and report waste generation (related to trash, recyclables, and construction & demolition debris) in your local jurisdictions (city, county, etc.)? (a.) What, if any, impact would this type of waste tracking and reporting have on the proposed rental rates for federal government leases? (5.) Given the thresholds of 25,000 rentable square feet or greater and at least 75 percent federal government occupancy, would any of the 5 key VerDate Sep<11>2014 17:11 Oct 04, 2024 Jkt 262001 sustainability solutions reflected in Section II of this RFI prevent building owners from offering space to the government on a competitive lease procurement? (6.) Are all or any of the 5 key sustainability solutions reflected in Section II of this RFI currently required by any building owners in jurisdictions or markets that you are familiar with (city, county, etc)? (a.) If so, which solutions, and which markets? (b.) Have building owners been able to meet the requirements like these in markets you are familiar with, and what impact, if any, have they had on rental rates? (7.) Please identify additional advanced sustainability requirements that GSA should consider in the pursuit of a more sustainable leased inventory. (a.) What are they? (b.) What are the expected impacts on rental rates for government leases associated with your recommendations? Crofton Whitfield, Assistant Commissioner, Office of Leasing, Public Buildings Service, General Services Administration. [FR Doc. 2024–23106 Filed 10–4–24; 8:45 am] BILLING CODE 6820–BT–P 81087 For further information on the meeting or the Green Book, please contact Carrie Morrison, Assistant Director, Financial Management and Assurance, MorrisonC@gao.gov or (202) 512–4689. To request a reasonable accommodation (RA) for this meeting, email GAO’s RA office at ReasonableAccommodations@ gao.gov. Please request all accommodations at least five business days prior to the meeting (by October 23, 2024). SUPPLEMENTARY INFORMATION: Any interested person may attend the virtual meeting as an observer. Members of the public will have an opportunity to address the Advisory Council with brief (five- minute) presentations on matters directly related to the proposed updates and revisions. Any interested person who plans to attend the virtual meeting as an observer must contact Carrie Morrison, Assistant Director, at (202) 512–4689, before October 23, 2024. The meeting agenda will be available upon request one week before the meeting. Authority: 31 U.S.C. 3512(c), (d). FOR FURTHER INFORMATION CONTACT: James R. Dalkin, Director, Financial Management and Assurance, U.S. Government Accountability Office. [FR Doc. 2024–23134 Filed 10–4–24; 8:45 am] GOVERNMENT ACCOUNTABILITY OFFICE BILLING CODE 1610–02–P Comptroller General’s Advisory Council on Standards for Internal Control in the Federal Government; Notice of Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES U.S. Government Accountability Office. ACTION: Notice of meeting. AGENCY: The U.S. Government Accountability Office (GAO) is revising the Standards for Internal Control in the Federal Government, known as the Green Book. As part of the revision process, GAO will hold a meeting of the Comptroller General’s Advisory Council on Standards for Internal Control in the Federal Government (Advisory Council) on Wednesday, October 30, 2024, from 10:00 a.m. to 1:00 p.m. to provide input and recommendations on revisions to the Green Book. The purpose of this meeting is to discuss proposed revisions as a result of comments received on the June 2024 Green Book Exposure Draft. The meeting will be virtual and is open to the public. DATES: The meeting will be held on Wednesday, October 30, 2024, from 10 a.m. to 1 p.m. ADDRESSES: The meeting will be virtual only. SUMMARY: PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 Request for Information (RFI): To Inform the Development of the 2026– 2030 National HIV/AIDS Strategy and the National Strategic Plans for Sexually Transmitted Infections, Vaccines, and Viral Hepatitis Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: Through this Request for Information (RFI), the Office of Infectious Disease and HIV/AIDS Policy (OIDP) in the Office of the Assistant Secretary for Health (OASH) in the Office of the Secretary, Department of Health and Human Services (HHS), invites feedback from Federal, State, Tribal, territorial, and local governments; community-based organizations and faith-based organizations; Urban Indian Organizations; health plans and payers; health care providers, and other healthrelated and social services SUMMARY: E:\FR\FM\07OCN1.SGM 07OCN1 lotter on DSK11XQN23PROD with NOTICES1 81088 Federal Register / Vol. 89, No. 194 / Monday, October 7, 2024 / Notices organizations; private-sector entities; researchers and academic institutions; people living with and who experience risk for disease; and other interested constituents on Strategic Plans to serve as national roadmaps to guide efforts to address HIV, sexually transmitted infections (STI), and viral hepatitis, and to improve and enhance the development and use of vaccines in the United States. DATES: To be assured consideration, comments must be received at the addresses provided below, no later than 5:00 p.m. ET on December 6, 2024. ADDRESSES: Submissions must be submitted electronically via the following website: https:// app.smartsheetgov.com/b/form/ 68aa1bd9c54b42829f99e85cc4ab1e82. FOR FURTHER INFORMATION CONTACT: Questions about this RFI should be directed to Nathan Fecik; Phone: 202– 795–7616; Email: Syndemics@hhs.gov. SUPPLEMENTARY INFORMATION: OIDP requests feedback on the development of the following (collectively referred to as the Strategic Plans): • National HIV/AIDS Strategy for the United States: 2026–2030 (NHAS) • Sexually Transmitted Infections National Strategic Plan for the United States: 2026–2030 (STI Plan) • Vaccines National Strategic Plan for the United States: 2026–2030 (Vaccines Plan) • Viral Hepatitis National Strategic Plan for the United States 2026–2030 (Viral Hepatitis Plan) The National HIV/AIDS Strategy for the United States: 2022–2025 (https:// files.hiv.gov/s3fs-public/NHAS-20222025.pdf), the Sexually Transmitted Infections National Strategic Plan for the United States: 2021–2025 (https:// www.hhs.gov/sites/default/files/STINational-Strategic-Plan-2021-2025.pdf), the Vaccines National Strategic Plan: 2021–2025 (https://www.hhs.gov/sites/ default/files/HHS-Vaccines-Report.pdf), and the Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination: 2021–2025 (https://www.hhs.gov/sites/default/files/ Viral-Hepatitis-National-Strategic-Plan2021-2025.pdf) expire at the end of calendar year 2025. OIDP, in collaboration with the White House Office of National AIDS Policy (focused specifically on the NHAS) and Federal partners, is leading work to develop the next iteration of these interrelated Strategic Plans through 2030. As the next NHAS will be developed in parallel with the three national strategic plans, OIDP is collecting information for the 2026– VerDate Sep<11>2014 17:11 Oct 04, 2024 Jkt 262001 2030 National HIV/AIDS Strategy at the request of the White House Office of National AIDS Policy. OIDP invites community input as people have served as the cornerstone for developing the Strategic Plans since their inception. Background: The Strategic Plans serve as national roadmaps for a broad range of constituents to help prevent, diagnose, treat, and cure disease, improve health outcomes, reduce health disparities and inequities, and advance research and technology. The plans include a common vision, overarching goals, objectives, and strategies, and indicators to measure national progress toward established targets. The development of the next iteration of the Strategic Plans will serve as an opportunity to incorporate the latest epidemiological data; review progress toward achieving national strategic plan goals; center the needs of populations disproportionately affected; address gaps identified in existing Strategic Plans; integrate the latest scientific advances; prioritize the most effective strategies for achieving national goals; and further emphasize the need to implement integrated syndemic approaches (https://www.hiv.gov/blog/ defining-the-term-syndemic) that cut across each of the Strategic Plans and address common root causes of infectious diseases. OIDP, in collaboration with Federal partners, is updating the Strategic Plans at the same time because these conditions often disproportionately affect similar populations and may share common root causes. The Vaccine National Strategic Plan is included in this coordinated process to elevate the critical role vaccines can serve as a key intervention to prevent infectious disease, including STIs and viral hepatitis, and to disrupt syndemics. By updating the Strategic Plans at the same time, OIDP aims to identify, leverage, and maximize Federal and other resources to achieve health equity and reduce related health disparities. OIDP coordinates the development, implementation, and monitoring of the Strategic Plans in collaboration with Federal partners. Information Requested: Anyone can submit written responses to the questions of interest listed at the following website: https:// app.smartsheetgov.com/b/form/ 68aa1bd9c54b42829f99e85cc4ab1e82. This feedback will inform the 2026– 2030 Strategic Plans. Please note that responses have specified word limits. Please provide evidence-based justification where applicable. Professional societies, advocacy organizations, and other groups are PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 encouraged to submit a single collective response that reflects the views of their membership. Responses to this RFI Notice are voluntary and may be made public by HHS. The submitted information will be reviewed by HHS staff and may be made available to the public, along with the submitting individual’s name, email address, and demographic information consisting of the submitter’s location, affiliated organization, role, and (if provided) title and nature of comments. Submitted information will not be considered confidential, so do not include proprietary, classified, confidential, personal, or other sensitive information in your response. This request is for information and planning purposes and should not be construed as a solicitation or as an obligation of the Federal Government or the HHS. No awards will be made based on responses to this RFI. The information submitted will be analyzed and may be used in reports or presentations. Those who respond are advised that the HHS is under no obligation to acknowledge receipt of your comments or provide feedback on your submission. The HHS and the government reserve the right to use any non-proprietary technical information in any future solicitation(s). Authority: 42 U.S.C. 202 and 42 U.S.C. 207. B. Kaye Hayes, Deputy Assistant Secretary for Infectious Disease; Director, Office of Infectious Disease and HIV/AIDS Policy. [FR Doc. 2024–22948 Filed 10–4–24; 8:45 am] BILLING CODE P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Proposed Collection; 60-Day Comment Request; Collection of Customer Service, Demographic, and Smoking/ Tobacco Use Information From the National Cancer Institute’s (NCI) Cancer Information Service (CIS) AGENCY: National Institutes of Health, HHS. ACTION: Notice. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide an opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. SUMMARY: E:\FR\FM\07OCN1.SGM 07OCN1

Agencies

[Federal Register Volume 89, Number 194 (Monday, October 7, 2024)]
[Notices]
[Pages 81087-81088]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22948]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Request for Information (RFI): To Inform the Development of the 
2026-2030 National HIV/AIDS Strategy and the National Strategic Plans 
for Sexually Transmitted Infections, Vaccines, and Viral Hepatitis

AGENCY: Office of Infectious Disease and HIV/AIDS Policy, Office of the 
Assistant Secretary for Health, Office of the Secretary, Department of 
Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Through this Request for Information (RFI), the Office of 
Infectious Disease and HIV/AIDS Policy (OIDP) in the Office of the 
Assistant Secretary for Health (OASH) in the Office of the Secretary, 
Department of Health and Human Services (HHS), invites feedback from 
Federal, State, Tribal, territorial, and local governments; community-
based organizations and faith-based organizations; Urban Indian 
Organizations; health plans and payers; health care providers, and 
other health-related and social services

[[Page 81088]]

organizations; private-sector entities; researchers and academic 
institutions; people living with and who experience risk for disease; 
and other interested constituents on Strategic Plans to serve as 
national roadmaps to guide efforts to address HIV, sexually transmitted 
infections (STI), and viral hepatitis, and to improve and enhance the 
development and use of vaccines in the United States.

DATES: To be assured consideration, comments must be received at the 
addresses provided below, no later than 5:00 p.m. ET on December 6, 
2024.

ADDRESSES: Submissions must be submitted electronically via the 
following website: https://app.smartsheetgov.com/b/form/68aa1bd9c54b42829f99e85cc4ab1e82.

FOR FURTHER INFORMATION CONTACT: Questions about this RFI should be 
directed to Nathan Fecik; Phone: 202-795-7616; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: OIDP requests feedback on the development of 
the following (collectively referred to as the Strategic Plans):

 National HIV/AIDS Strategy for the United States: 2026-2030 
(NHAS)
 Sexually Transmitted Infections National Strategic Plan for 
the United States: 2026-2030 (STI Plan)
 Vaccines National Strategic Plan for the United States: 2026-
2030 (Vaccines Plan)
 Viral Hepatitis National Strategic Plan for the United States 
2026-2030 (Viral Hepatitis Plan)

    The National HIV/AIDS Strategy for the United States: 2022-2025 
(https://files.hiv.gov/s3fs-public/NHAS-2022-2025.pdf), the Sexually 
Transmitted Infections National Strategic Plan for the United States: 
2021-2025 (https://www.hhs.gov/sites/default/files/STI-National-Strategic-Plan-2021-2025.pdf), the Vaccines National Strategic Plan: 
2021-2025 (https://www.hhs.gov/sites/default/files/HHS-Vaccines-Report.pdf), and the Viral Hepatitis National Strategic Plan for the 
United States: A Roadmap to Elimination: 2021-2025 (https://www.hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf) expire at the end of calendar year 2025.
    OIDP, in collaboration with the White House Office of National AIDS 
Policy (focused specifically on the NHAS) and Federal partners, is 
leading work to develop the next iteration of these interrelated 
Strategic Plans through 2030. As the next NHAS will be developed in 
parallel with the three national strategic plans, OIDP is collecting 
information for the 2026-2030 National HIV/AIDS Strategy at the request 
of the White House Office of National AIDS Policy. OIDP invites 
community input as people have served as the cornerstone for developing 
the Strategic Plans since their inception.
    Background: The Strategic Plans serve as national roadmaps for a 
broad range of constituents to help prevent, diagnose, treat, and cure 
disease, improve health outcomes, reduce health disparities and 
inequities, and advance research and technology. The plans include a 
common vision, overarching goals, objectives, and strategies, and 
indicators to measure national progress toward established targets.
    The development of the next iteration of the Strategic Plans will 
serve as an opportunity to incorporate the latest epidemiological data; 
review progress toward achieving national strategic plan goals; center 
the needs of populations disproportionately affected; address gaps 
identified in existing Strategic Plans; integrate the latest scientific 
advances; prioritize the most effective strategies for achieving 
national goals; and further emphasize the need to implement integrated 
syndemic approaches (https://www.hiv.gov/blog/defining-the-term-syndemic) that cut across each of the Strategic Plans and address 
common root causes of infectious diseases.
    OIDP, in collaboration with Federal partners, is updating the 
Strategic Plans at the same time because these conditions often 
disproportionately affect similar populations and may share common root 
causes. The Vaccine National Strategic Plan is included in this 
coordinated process to elevate the critical role vaccines can serve as 
a key intervention to prevent infectious disease, including STIs and 
viral hepatitis, and to disrupt syndemics. By updating the Strategic 
Plans at the same time, OIDP aims to identify, leverage, and maximize 
Federal and other resources to achieve health equity and reduce related 
health disparities.
    OIDP coordinates the development, implementation, and monitoring of 
the Strategic Plans in collaboration with Federal partners.
    Information Requested: Anyone can submit written responses to the 
questions of interest listed at the following website: https://app.smartsheetgov.com/b/form/68aa1bd9c54b42829f99e85cc4ab1e82.
    This feedback will inform the 2026-2030 Strategic Plans. Please 
note that responses have specified word limits. Please provide 
evidence-based justification where applicable. Professional societies, 
advocacy organizations, and other groups are encouraged to submit a 
single collective response that reflects the views of their membership.
    Responses to this RFI Notice are voluntary and may be made public 
by HHS. The submitted information will be reviewed by HHS staff and may 
be made available to the public, along with the submitting individual's 
name, email address, and demographic information consisting of the 
submitter's location, affiliated organization, role, and (if provided) 
title and nature of comments. Submitted information will not be 
considered confidential, so do not include proprietary, classified, 
confidential, personal, or other sensitive information in your 
response. This request is for information and planning purposes and 
should not be construed as a solicitation or as an obligation of the 
Federal Government or the HHS. No awards will be made based on 
responses to this RFI. The information submitted will be analyzed and 
may be used in reports or presentations. Those who respond are advised 
that the HHS is under no obligation to acknowledge receipt of your 
comments or provide feedback on your submission. The HHS and the 
government reserve the right to use any non-proprietary technical 
information in any future solicitation(s).
    Authority: 42 U.S.C. 202 and 42 U.S.C. 207.

B. Kaye Hayes,
Deputy Assistant Secretary for Infectious Disease; Director, Office of 
Infectious Disease and HIV/AIDS Policy.
[FR Doc. 2024-22948 Filed 10-4-24; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.